Clinical Trial Update: A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B [Phase 4]

View source ↗

Summary

Phase 4 study update on peginterferon alfa-2a (PEGASYS) in participants with HBeAg-positive chronic hepatitis B; the trial completed with results posted in Octo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2016-10-24